User:Mr. Ibrahem/Daclizumab

Daclizumab, sold under the brand name Zinbryta among others, was a medication used to treat the relapsing forms of multiple sclerosis (MS) and prevent rejection after a kidney transplant. It was given by injection under the skin or into a vein.

Common side effects include upper respiratory tract infection, rash, depression, and liver problems such as autoimmune hepatitis. Other health problems may include suicide, infection, colitis, and anaphylaxis. It is a monoclonal antibody which binds to CD25 on T-cells inhibiting them.

Daclizumab was approved for medical use in Europe in 1999 and the United States in 2016. In 2018, it was withdrawn from market globally after reports of autoimmune encephalitis in Europe.